Alexion Prepares To Launch Soliris In Japan Following Record NHI Price Listing Time
This article was originally published in PharmAsia News
Executive Summary
Japan's Central Social Medical Insurance Agency (Chuikyo) approved Soliris (eculizumab) National Health Insurance price listing at its June meeting, three months ahead of a previously estimated fall listing, and Soliris maker Alexion Pharmaceutical is gearing up for an earlier launch in Japan
You may also be interested in...
Emerging Views On Emerging Markets: Leerink Swann Global Healthcare Conference
PharmAsia News takes a closer look at presentations by Alexion, Amgen, J&J, Merck and Novartis during one of the industry’s major investor conferences.
Australia Questions Soliris Survival Benefit; Adds Listings From MSD, Novartis, Janssen To PBS
PERTH, Australia - Australia's Minister of Health Nicola Roxon requested advice from the Pharmaceutical Benefits Advisory Committee on the potential benefits of adding Alexion's Soliris (eculizumab) to the government's Life Saving Drugs Program (LSDP)
Australia Questions Soliris Survival Benefit; Adds Listings From MSD, Novartis, Janssen To PBS
PERTH, Australia - Australia's Minister of Health Nicola Roxon requested advice from the Pharmaceutical Benefits Advisory Committee on the potential benefits of adding Alexion's Soliris (eculizumab) to the government's Life Saving Drugs Program (LSDP)